Author

Brook Croke

February 9, 2024

Why Genetic Testing is Valuable for Individuals with Neurodegenerative Disorders

Clarifying the odd that a diagnosis is genetic in nature
February 9, 2024

First Gene-Specific ALS Treatment Approved on DNA Day

Biogen’s QALSODY receives accelerated approval by the FDA for SOD1-ALS
February 9, 2024

Baking with Barb

My name is Brook and I am a genetic counselor at Synapticure. I’d like to share my personal experience with ALS and how it motivates me in my work at Synapticure.

It is time to leave behind the era of

“I’m sorry but we can’t help you.”

Book your visit
Patients & Families
How It WorksFrequently Asked Questions
For Partners
ProvidersPayersGUIDEResearch
Our Services
Alzheimer's DiseaseFrontotemporal DementiaALS & PLSParkinson's DiseaseHuntington's DiseaseMental Health Care
About us
Leadership TeamOur CliniciansCareersCollaborators & SupportersContact
Resources
Our BlogPress Releases
Legal
Privacy PolicyTerms of ServiceNotice of Privacy PracticesConsumer Health Data Privacy PolicyTelehealth Informed ConsentFCOINondiscrimination Notice

This office appreciates the diversity of human beings and does not discriminate based on race, age, religion, ability,  marital status, sexual orientation, sex or gender identity.

Synapticure logo whitePh: +1 708-630-1534
Fax: +1 888-517-8619

2045 W Grand Ave Ste B Chicago, IL 60612

AICPA SOC 2 logo
© Copyright Synapticure. All rights reserved.